LSP 7 lifts Evommune (NASDAQ: EVMN) stake to 14.7%

Rhea-AI Filing Summary

Evommune, Inc. received a new investment from LSP 7 through a February 2026 private placement. The company sold 4,494,279 common shares at $27.88 per share to institutional investors, including LSP 7, raising additional equity capital.

LSP 7 purchased 358,680 shares for total consideration of $9,999,998.40 and now beneficially owns 5,288,313 Evommune shares, representing about 14.7% of the 36,018,372 shares outstanding after the closing. LSP 7 Management B.V., a Netherlands entity, is the sole director of LSP 7.

In connection with the transaction, Evommune agreed to file a Form S-1 registration statement to register the resale of the private placement shares within 60 days of the February 17, 2026 closing and to use reasonable best efforts to keep that registration effective until the shares can be freely resold.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Evommune, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

30054Y107

(CUSIP Number)

Bas Vaessen
LSP 7 Management B.V., Johannes Vermeerplein 9
Amsterdam, P7, 1071 DV
31206645500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 30054Y107

1

Name of reporting person

LSP 7 Cooperatieve U.A.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,288,313.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,288,313.00

11

Aggregate amount beneficially owned by each reporting person

5,288,313.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.7 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 30054Y107

1

Name of reporting person

LSP 7 Management B.V.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,288,313.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,288,313.00

11

Aggregate amount beneficially owned by each reporting person

5,288,313.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.7 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: Evommune, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1841 Page Mill Road, Suite 100, Palo Alto, CALIFORNIA , 94304.
Item 1 Comment: Explanatory Note This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on November 14, 2025 (as amended to date, the "Schedule 13D"), relating to the shares of common stock, $0.0001 par value per share (the "Common Stock"), of Evommune, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and supplemented as follows: February 2026 Securities Purchase Agreement On February 12, 2026, the Issuer entered into a securities purchase agreement (the "February 2026 Securities Purchase Agreement") with certain institutional accredited investors (the "February 2026 PIPE Investors"), including LSP 7, pursuant to which the Issuer agreed to issue and sell to the February 2026 PIPE Investors in a private placement (the "February 2026 Private Placement") an aggregate of 4,494,279 shares of Common Stock (the "Shares") at a price of $27.88 per share. The February 2026 Private Placement closed on February 17, 2026 (the "Closing Date"). LSP 7 purchased 358,680 Shares for total consideration of $9,999,998.40, which was funded through capital contributions from its members. The foregoing description of the February 2026 Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Securities Purchase Agreement, a copy of which is filed as Exhibit 4 hereto and incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	The ownership information presented herein represents beneficial ownership of Common Stock as of the date hereof, based on 36,018,372 shares of Common Stock outstanding following the Closing Date. LSP 7 is the record holder of the shares of Common Stock reported herein and is the beneficial owner of approximately 14.7% of the outstanding shares of Common Stock. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
(b)	Sole power to vote or to direct the vote: 0 Shared power to vote or to direct the vote: 5,288,313 Sole power to dispose or to direct the disposition of: 0 Shared power to dispose or to direct the disposition of: 5,288,313
(c)	Except as set forth in this Amendment No. 1, during the past 60 days, none of the Reporting Persons nor the Related Persons have effected any transactions in the Common Stock.
(d)	None.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 of the Schedule 13D is hereby amended and supplemented as follows: Item 3 of the Schedule 13D is incorporated by reference herein. In connection with the February 2026 Private Placement, the Issuer also entered into a Registration Rights Agreement, dated February 12, 2026 (the "February 2026 Registration Rights Agreement"), with the February 2026 PIPE Investors. Pursuant to the terms of the February 2026 Registration Rights Agreement, the Issuer is obligated to prepare and file with the SEC a registration statement on Form S-1 (the "Registration Statement") to register for resale of the Shares within 60 days of the Closing Date and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 90 days after the initial filing date of the Registration Statement, subject to extension under the terms of the February 2026 Registration Rights Agreement. The Issuer also agreed to use reasonable best efforts to keep such Registration Statement effective until the earlier of the date the Shares covered by such Registration Statement have been sold or may be resold pursuant to Rule 144 without restriction. The February 2026 Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification. The foregoing description of the February 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Registration Rights Agreement, a copy of which is filed as Exhibit 5 hereto and incorporated by reference herein.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 4: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on February 13, 2026). Exhibit 5: Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on February 13, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LSP 7 Cooperatieve U.A.

Signature:	By: LSP 7 Management B.V., its sole director, By: /s/ Martijn Kleijwegt
Name/Title:	Martijn Kleijwegt, Managing Director
Date:	02/19/2026

Signature:	By: LSP 7 Management B.V., its sole director, By: /s/ Rene Kuijten
Name/Title:	Rene Kuijten, Managing Director
Date:	02/19/2026

LSP 7 Management B.V.

Signature:	/s/ Martijn Kleijwegt
Name/Title:	Martijn Kleijwegt, Managing Director
Date:	02/19/2026

Signature:	/s/ Rene Kuijten
Name/Title:	Rene Kuijten, Managing Director
Date:	02/19/2026

FAQ

What stake does LSP 7 hold in Evommune (EVMN) after this amendment?

LSP 7 beneficially owns 5,288,313 shares of Evommune common stock, representing about 14.7% of the 36,018,372 shares outstanding after the private placement closing. This Schedule 13D/A updates its ownership disclosure following the February 2026 financing.

How many Evommune (EVMN) shares did LSP 7 buy in the February 2026 PIPE?

LSP 7 purchased 358,680 Evommune common shares in the February 2026 private placement at $27.88 per share. The total consideration was $9,999,998.40, funded through capital contributions from LSP 7’s members, increasing its overall beneficial ownership.

What were the terms of Evommune’s February 2026 private placement?

Evommune agreed to sell an aggregate 4,494,279 common shares at $27.88 per share to institutional investors, including LSP 7. The private placement closed on February 17, 2026, increasing the company’s outstanding shares to 36,018,372 immediately following the closing date.

What registration rights did Evommune (EVMN) grant for the PIPE shares?

Evommune entered a Registration Rights Agreement requiring it to file a Form S-1 within 60 days of the February 17, 2026 closing. The company must use reasonable best efforts to have it declared effective and keep it effective until the shares can be resold freely.

Who controls the Evommune (EVMN) shares reported by LSP 7?

LSP 7 is the record holder and reports shared voting and dispositive power over 5,288,313 shares. LSP 7 Management B.V. is LSP 7’s sole director, whose managing directors are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe, overseeing decisions for these holdings.